Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of nemorubicin versus doxorubicin in unresectable hepatocellular carcinoma
2006-000798-31Phase 2Terminated
- Sponsor
- Nerviano Medical Sciences
- Start
- Oct 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Nemorubicin hydrochloride with Doxorubicin hydrochloride (2 arms). Primary endpoint: Survival at 7 months. Started Oct 2006; status: terminated.
02
Drugs
nemorubicindoxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2006-000798-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000798-31.